Scholarlink

Background <p>Alzheimer’s disease is a progressive neurodegenerative disease where the existing oral therapies are limited due to poor bioavailability, gastrointestinal side effects, and lack of brain-blood barrier crossing. Dissolving microneedles have become a low-invasive form of transdermal drug delivery system that potentially overcomes these drawbacks by circumventing the first-pass metabolism and increasing systemic absorption.</p> Main body <p>This systematic review is an evaluation of the potential of dissolving microneedles to administer anti-Alzheimer drugs in preclinical trials. A detailed search of the literature (PubMed, Scopus, and Google Scholar) was conducted without date limitations, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Among the 3,387 studies identified, 11 met the inclusion criteria. The studies selected examined the use of dissolving microneedle systems to deliver agents such as Donepezil, Rivastigmine, Huperzine A, Telmisartan, and others. In all studies, there was enhanced absorption of dissolved microneedles, increased permeability of the biologic barrier, and desirable safety profiles compared with traditional administration routes. Some studies also showed improved cognitive outcomes in models of Alzheimer’s disease. Microneedle designs with tip loading allowed an increased loading of drugs at the tip of the needle, and the rapid dissolution in interstitial fluid following painless penetration of the stratum corneum. This enabled the administration of therapeutic agents effectively into the systemic circulation. Microneedle geometry, fabrication materials and composition affected the efficacy of these systems.</p> Conclusion <p>Dissolving microneedles are an innovative approach to delivering anti-Alzheimer drugs transdermally, offering improved bioavailability and safety and the potential to target the brain. Their clinical applicability and the optimal use of their formulation parameters in humans should be validated through further research.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advancement in dissolving microneedles drug delivery system for the management of Alzheimer’s disease: a systematic review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月24日

查看全文
  • Adnan Khan,
  • Molakpogu Ravindra Babu,
  • Balamurugan Balusamy,
  • Arya Tripathi,
  • Shriyansh Srivastava,
  • Manish Vyas,
  • Rishabha Malviya

摘要

Background

Alzheimer’s disease is a progressive neurodegenerative disease where the existing oral therapies are limited due to poor bioavailability, gastrointestinal side effects, and lack of brain-blood barrier crossing. Dissolving microneedles have become a low-invasive form of transdermal drug delivery system that potentially overcomes these drawbacks by circumventing the first-pass metabolism and increasing systemic absorption.

Main body

This systematic review is an evaluation of the potential of dissolving microneedles to administer anti-Alzheimer drugs in preclinical trials. A detailed search of the literature (PubMed, Scopus, and Google Scholar) was conducted without date limitations, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Among the 3,387 studies identified, 11 met the inclusion criteria. The studies selected examined the use of dissolving microneedle systems to deliver agents such as Donepezil, Rivastigmine, Huperzine A, Telmisartan, and others. In all studies, there was enhanced absorption of dissolved microneedles, increased permeability of the biologic barrier, and desirable safety profiles compared with traditional administration routes. Some studies also showed improved cognitive outcomes in models of Alzheimer’s disease. Microneedle designs with tip loading allowed an increased loading of drugs at the tip of the needle, and the rapid dissolution in interstitial fluid following painless penetration of the stratum corneum. This enabled the administration of therapeutic agents effectively into the systemic circulation. Microneedle geometry, fabrication materials and composition affected the efficacy of these systems.

Conclusion

Dissolving microneedles are an innovative approach to delivering anti-Alzheimer drugs transdermally, offering improved bioavailability and safety and the potential to target the brain. Their clinical applicability and the optimal use of their formulation parameters in humans should be validated through further research.